Anastasia Snuszka
Family · Tonawanda, NYNPI 1124695424
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.7% of the total across 190 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 23.8% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,108, more than ten times the $17 reported in 2021. Among family clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 190 payments — averaging $21.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$981
- Regeneron Healthcare Solutions, Inc.$715
- GSK$425
- AstraZeneca$389
- CSL Behring$233
- ARS Pharmaceuticals Operations, Inc.$230
- plus $1K from 20 others
What the payments were for
- Food & beverage$3,89995%
- Education$2185%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 43 | $981 |
| Regeneron Healthcare Solutions, Inc. | 44 | $715 |
| GSK | 23 | $425 |
| AstraZeneca | 18 | $389 |
| CSL Behring | 5 | $233 |
| ARS Pharmaceuticals Operations, Inc. | 9 | $230 |
| Amgen | 7 | $168 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $121 |
| Sanofi-aventis U.S. LLC | 1 | $99 |
| Biocryst US Sales Co., LLC | 5 | $98 |
| Pfizer | 4 | $89 |
| Merck | 5 | $88 |
| Genentech USA, Inc. | 3 | $84 |
| Sanofi Pasteur Inc. | 2 | $61 |
| Octapharma USA, Inc. | 3 | $60 |
| Pharming Healthcare, Inc. | 2 | $46 |
| Kaleo, Inc. | 2 | $46 |
| Grifols USA, LLC | 2 | $35 |
| Blueprint Medicines Corporation | 1 | $25 |
| Nestle Healthcare Nutrition Inc. | 1 | $24 |
| Boehringer Ingelheim | 1 | $19 |
| Galderma Laboratories, L.p. | 1 | $18 |
| Bio Products Laboratory USA, Inc. | 1 | $17 |
| Alk-abello, Inc | 1 | $17 |
| AbbVie | 1 | $16 |
| Organon | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,117 in reported general payments places this provider in the 90th percentile of 8,883 family providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $8,058 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 35 | $6,484 |
| Spiriva RespimatTiotropium Bromide | 11 | $5,564 |
| Epinephrine | 13 | $3,846 |
| Azelastine Hcl | 61 | $1,464 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 47 | $1,341 |
| Fluticasone Propionate | 56 | $712 |
| Levocetirizine Dihydrochloride | 22 | $237 |
| Famotidine | 16 | $130 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $425 | $8,05813 claims |
| Boehringer IngelheimSpiriva Respimat | $19 | $5,56411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,883 family providers in New York.
Other family in Tonawanda
- Christina NalboneNew York$197K
- Casey GrilloNew York$191K
- Suzanne WilsonIthaca$179K
- Jonathan LesuerSyracuse$172K
- Sheri HillNorth Syracuse$165K
- Cathrine CurtinBronxville$155K
- Mary Sullivan-WhalenNew York$137K
- Sarah AljahmiRockville Centre$87K
- John de OcaStaten Island$86K
- Fara StrickerGlen Oaks$85K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.